查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402027

2030 年肺炎檢測市場預測：按產品類型、測試類型、測試方法、技術、最終用戶和地區進行的全球分析

Pneumonia Testing Market Forecasts to 2030 - Global Analysis By Product Type, Type, Test Type, Method, Technology, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肺炎檢測市場規模為 6.5513 億美元，預計到 2030 年將達到 11.2277 億美元，預測期內複合年成長率為 8.0%。

一種稱為肺炎測試的重要診斷程序用於確定是否存在肺炎（一種導致肺部氣囊發炎的呼吸道感染疾病）。肺炎通常由細菌、病毒和真菌引起。如果不治療，可能會出現嚴重的呼吸問題。胸部 X 光檢查可用於檢查肺部是否異常，血液檢查可用於確定是否有感染，分析呼吸道分泌物可確定原因。

根據美國美國衛生研究院 (NIH) 2022 年發表的論文，肺炎球菌占美國肺炎病例的 15.0%，全球整體肺炎病例的 27.0%。

人口高齡化與傳染病風險

推動肺炎檢測市場的關鍵因素之一是人口結構向高齡化社會的變化。老年人更容易受到包括肺炎在內的呼吸道感染疾病，這增加了準確檢測方法的需求。此外，這個人口因素凸顯了市場對早期發現和滿足高齡化人口獨特的醫療保健需求的責任。

尖端診斷系統的初期成本較高

肺炎檢測​​市場的一個障礙是與先進診斷技術相關的初期成本。較新的設備，例如先進的影像技術和分子診斷，可能具有較高的初期成本。此外，它可能會減緩這些尖端測試技術的市場滲透並限制其採用，特別是在資源有限的醫療保健環境中。

多重測試平台開發

肺炎檢測​​市場的開拓將由可同時檢測多種病原體的多重檢測平台的發展所推動。透過在單次測試中提供完整的診斷資料並加快診斷過程，這些平台提高了生產效率。此外，檢測合併感染和提高整體診斷準確性是多重檢測特別有用的兩個領域。

衛生系統的財政限制

先進肺炎檢測技術的普及受到衛生系統預算限制的威脅。資金有限可能導致難以投資培訓衛生工作者和購買尖端診斷工具。此外，這可能會導致無法平等地獲得最先進的檢測技術，並損害肺炎診斷的整體有效性。

COVID-19 的影響：

COVID-19 大流行改變了醫療保健行業的動態和優先事項，對肺炎檢測市場產生了重大影響。隨著疫情提高了人們對呼吸系統健康的興趣以及對診斷解決方案的需求激增，肺炎檢測的創新正在加速。另一方面，供應鏈中斷、醫療支出波動以及高峰時期對偵測資源的巨大需求等挑戰也構成了巨大的障礙。此外，這場大流行凸顯了可擴展且有效的肺炎檢測在全球突發衛生事件中發揮的關鍵作用，迫使該行業進行創新並適應感染疾病不斷變化的性質。

預計預測期內病毒性肺炎領域規模最大

就肺炎檢測的市場佔有率而言，病毒性肺炎細分市場預計將佔據最大佔有率。由於流感和呼吸道融合細胞病毒（RSV）等呼吸道病毒的爆發，以及以新型冠狀病毒SARS-CoV-2 為主要原因的 COVID-19 大流行，病毒性肺炎受到關注。對病毒性肺炎專門診斷解決方案的需求不斷增加，導致分子測定、抗原測試和其他診斷技術的進步。此外，呼吸道病毒的傳染性以及準確快速檢測的需求使該領域成為肺炎檢測市場的重點。

診斷實驗室部門預計在預測期內複合年成長率最高

在肺炎檢測市場中，診斷實驗室部門預計將以最高的複合年成長率成長。診斷實驗室提供影像檢查、血液檢查、分子診斷等多種診斷工具，對於提供全面、專業的肺炎檢測服務至關重要。由於診斷技術的進步以及對快速、準確的肺炎檢測的需求不斷成長，診斷檢測設施不斷發展。此外，這些設施採用最先進的診斷技術，並且通常配備精良，可以有效地處理大量測試。

佔有率最大的地區：

預計北美地區將佔據肺炎檢測的最大市場佔有率。該地區的優勢在於其強大的醫療基礎設施、最先進的診斷技術以及對感染疾病的積極控制。此外，有利的報銷政策、意識的提高以及北美呼吸道感染疾病的高盛行率也推動了對肺炎檢測的需求。

複合年成長率最高的地區：

預計亞太地區肺炎檢測市場的複合年成長率最高。這是由於亞太國家呼吸道感染疾病上升、人口高齡化、衛生基礎設施支出增加以及越來越重視加強醫療保健服務。此外，該地區的經濟成長、醫療技術的進步以及公眾對早期診斷價值的認知不斷提高正在推動高成長。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肺炎檢測市場：依產品類型

  • 介紹
  • 消耗品及試劑
  • 裝置
  • 分析儀
  • 其他產品類型

第6章全球肺炎檢測市場：依類型

  • 介紹
  • 鏈球菌
  • 退伍軍人菌
  • 衣原體
  • 病毒性肺炎
  • 黴漿菌肺炎
  • 其他類型

第7章全球肺炎檢測市場：依檢測類型

  • 介紹
  • 驗血
  • 影像檢查
  • 痰測試
  • 尿液檢查
  • 其他測試類型

第8章全球肺炎檢測市場：依方法分類

  • 介紹
  • 分子診斷
  • 即時檢測
  • 免疫診斷
  • 其他方法

第9章全球肺炎檢測市場：依技術分類

  • 介紹
  • 酵素免疫吸附測定
  • 螢光
  • 西方墨點法
  • 聚合酶鍊式反應
  • 免疫組織化學
  • 其他技術

第10章 全球肺炎檢測市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 診斷實驗室
  • 居家醫療
  • 其他最終用戶

第11章 全球肺炎檢測市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Danaher
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Beckton and Dickinson Company
  • Cepheid
  • Biomerieux SA
  • Hologic Inc
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Bio Rad laboratories
  • OpGen
  • Quidel Corporation
  • AdvanDx
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated
Product Code: SMRC24547

According to Stratistics MRC, the Global Pneumonia Testing Market is accounted for $655.13 million in 2023 and is expected to reach $1122.77 million by 2030 growing at a CAGR of 8.0% during the forecast period. A vital diagnostic procedure called pneumonia testing is used to determine whether pneumonia-a respiratory infection that inflames the lungs' air sacs-is present. Pneumonia is frequently caused by bacteria, viruses, or fungi. If treatment is not received, it can result in severe respiratory distress. Chest X-rays can be used to see abnormalities in the lungs; blood tests can determine whether an infection is present; and respiratory secretion analysis can pinpoint the cause.

According to a published article by the National Institutes of Health (NIH) in 2022, streptococcus pneumoniae accounts for up to 15.0% of pneumonia cases in the U.S. and 27.0% globally.

Market Dynamics:

Driver:

Population aging and contagious disease risk

One major factor driving the market for pneumonia testing is the demographic shift towards an aging population. There is an increased need for accurate testing procedures because elderly people are more vulnerable to respiratory infections, including pneumonia. Moreover, this demographic factor highlights early detection and the market's responsibility to meet the unique healthcare needs of the aging population.

Restraint:

High initial expenses for cutting-edge diagnostic systems

A barrier to the market for pneumonia testing is the upfront expenses linked to sophisticated diagnostic technologies. Modern instruments like sophisticated imaging technology and molecular diagnostics can be highly expensive up front. Additionally, this could slow down the market penetration of these cutting-edge testing techniques and restrict their adoption, especially in healthcare settings with limited resources.

Opportunity:

Development of platforms for multiplex testing

Pneumonia testing market opportunities are presented by the development of multiplex testing platforms, which can detect multiple pathogens simultaneously. By delivering thorough diagnostic data in a single test and expediting the diagnostic procedure, these platforms increase productivity. Furthermore, discovering co-infections and enhancing overall diagnostic accuracy are two areas in which multiplex testing is especially helpful.

Threat:

Financial limitations in healthcare systems

The widespread adoption of advanced pneumonia testing technologies is threatened by budgetary constraints in healthcare systems. Limited funds may make it more difficult to invest in healthcare personnel's training and to purchase cutting-edge diagnostic tools. Moreover, this may result in unequal access to cutting-edge testing techniques, which could compromise the overall efficacy of pneumonia diagnosis.

COVID-19 Impact:

The COVID-19 pandemic has changed dynamics and priorities in the healthcare sector, which has had a significant effect on the market for pneumonia tests. Pneumonia testing innovation has accelerated due to the pandemic's increased focus on respiratory health and the pressing need for diagnostic solutions. On the other hand, difficulties like supply chain disruptions, fluctuating healthcare spending, and the tremendous demand for testing resources at peak times have also presented formidable obstacles. Additionally, the pandemic has brought to light the critical role that scalable and effective pneumonia testing plays in international health emergencies, and this has forced the industry to innovate and adapt to the changing nature of infectious diseases.

The Viral Pneumonia segment is expected to be the largest during the forecast period

In terms of market share for pneumonia tests, the viral pneumonia segment is projected to hold the largest share. Viral pneumonia has received a lot of attention because of the prevalence of respiratory viruses like influenza and respiratory syncytial virus (RSV) as well as the COVID-19 pandemic, which was primarily caused by the novel coronavirus SARS-CoV-2. Molecular assays, antigen tests, and other diagnostic techniques have advanced as a result of the growth in demand for viral pneumonia-specific diagnostic solutions. Moreover, this segment has become a crucial focal point in the pneumonia testing market due to the contagious nature of respiratory viruses and the need for accurate and quick testing.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market for pneumonia testing, the diagnostic laboratory segment is anticipated to grow at the highest CAGR. Diagnostic laboratories, which provide a variety of diagnostic modalities like imaging studies, blood tests, and molecular diagnostics, are essential to the provision of thorough and specialized testing services for pneumonia. Diagnostic laboratories have grown as a result of improvements in diagnostic technologies and the growing need for quick and accurate testing for pneumonia. Additionally, these facilities are frequently at the forefront of adopting cutting-edge diagnostic techniques and are outfitted to efficiently handle a high volume of tests.

Region with largest share:

The region of North America is projected to have the largest market share for pneumonia testing. The region's prominence is attributed to its strong healthcare infrastructure, cutting-edge diagnostic technologies, and proactive management of infectious diseases. Furthermore, the demand for pneumonia testing is driven by favorable reimbursement policies, heightened awareness, and a higher prevalence of respiratory infections in North America.

Region with highest CAGR:

In the market for pneumonia testing, the Asia-Pacific region is projected to have the highest CAGR. The rising incidence of respiratory infections, the aging population, the increased spending on healthcare infrastructure, and the increased emphasis on enhancing healthcare accessibility in Asia-Pacific nations are some of the causes of this. Moreover, the high growth is a result of the region's growing economies, improvements in healthcare technologies, and increased public awareness of the value of early diagnosis.

Key players in the market:

Some of the key players in Pneumonia Testing market include Danaher , Abbott, F. Hoffmann-La Roche Ltd., Beckton and Dickinson Company, Cepheid, Biomerieux SA, Hologic Inc, Luminex Corporation, Meridian Bioscience, Inc., Bio Rad laboratories, OpGen, Quidel Corporation, AdvanDx, Thermo Fisher Scientific Inc., Beckman Coulter , Siemens Healthcare GmbH and Quest Diagnostics Incorporated .

Key Developments:

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In September 2023, Hologic and Bayer today announced an international partnership focused on improving breast cancer detection. The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality, combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.

In August 2023, Science and medical technology firm Danaher announced Monday that it has entered into an agreement to acquire Abcam, a Cambridge, U.K.-based supplier of antibodies, reagents, biomarkers, and assays. Under the agreement, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash.

Product Types Covered:

  • Consumables & Reagents
  • Instruments
  • Analyzers
  • Other Product Types

Types Covered:

  • Streptococcus
  • Legionella
  • Chlamydophila
  • Viral Pneumonia
  • Mycoplasma Pneumonia
  • Other Types

Test Types Covered:

  • Blood Test
  • Imaging Test
  • Sputum Test
  • Urine Test
  • Other Test Types

Methods Covered:

  • Molecular Diagnostics
  • Point of Care Testing
  • Immunodiagnostics
  • Other Methods

Technologies Covered:

  • Enzyme Linked Immunosorbant Assay
  • Immunofluoroscence
  • Western Blot
  • Polymerase Chain Reaction
  • Imunohistochemistry
  • Other Technologies

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pneumonia Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Consumables & Reagents
  • 5.3 Instruments
  • 5.4 Analyzers
  • 5.5 Other Product Types

6 Global Pneumonia Testing Market, By Type

  • 6.1 Introduction
  • 6.2 Streptococcus
  • 6.3 Legionella
  • 6.4 Chlamydophila
  • 6.5 Viral Pneumonia
  • 6.6 Mycoplasma Pneumonia
  • 6.7 Other Types

7 Global Pneumonia Testing Market, By Test Type

  • 7.1 Introduction
  • 7.2 Blood Test
  • 7.3 Imaging Test
  • 7.4 Sputum Test
  • 7.5 Urine Test
  • 7.6 Other Test Types

8 Global Pneumonia Testing Market, By Method

  • 8.1 Introduction
  • 8.2 Molecular Diagnostics
  • 8.3 Point of Care Testing
  • 8.4 Immunodiagnostics
  • 8.5 Other Methods

9 Global Pneumonia Testing Market, By Technology

  • 9.1 Introduction
  • 9.2 Enzyme Linked Immunosorbant Assay
  • 9.3 Immunofluoroscence
  • 9.4 Western Blot
  • 9.5 Polymerase Chain Reaction
  • 9.6 Imunohistochemistry
  • 9.7 Other Technologies

10 Global Pneumonia Testing Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Diagnostic Laboratories
  • 10.4 Homecare
  • 10.5 Other End Users

11 Global Pneumonia Testing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Danaher
  • 13.2 Abbott
  • 13.3 F. Hoffmann-La Roche Ltd.
  • 13.4 Beckton and Dickinson Company
  • 13.5 Cepheid
  • 13.6 Biomerieux SA
  • 13.7 Hologic Inc
  • 13.8 Luminex Corporation
  • 13.9 Meridian Bioscience, Inc.
  • 13.10 Bio Rad laboratories
  • 13.11 OpGen
  • 13.12 Quidel Corporation
  • 13.13 AdvanDx
  • 13.14 Thermo Fisher Scientific Inc.
  • 13.15 Beckman Coulter
  • 13.16 Siemens Healthcare GmbH
  • 13.17 Quest Diagnostics Incorporated

List of Tables

  • Table 1 Global Pneumonia Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pneumonia Testing Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Pneumonia Testing Market Outlook, By Consumables & Reagents (2021-2030) ($MN)
  • Table 4 Global Pneumonia Testing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 5 Global Pneumonia Testing Market Outlook, By Analyzers (2021-2030) ($MN)
  • Table 6 Global Pneumonia Testing Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 7 Global Pneumonia Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 8 Global Pneumonia Testing Market Outlook, By Streptococcus (2021-2030) ($MN)
  • Table 9 Global Pneumonia Testing Market Outlook, By Legionella (2021-2030) ($MN)
  • Table 10 Global Pneumonia Testing Market Outlook, By Chlamydophila (2021-2030) ($MN)
  • Table 11 Global Pneumonia Testing Market Outlook, By Viral Pneumonia (2021-2030) ($MN)
  • Table 12 Global Pneumonia Testing Market Outlook, By Mycoplasma Pneumonia (2021-2030) ($MN)
  • Table 13 Global Pneumonia Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 14 Global Pneumonia Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 15 Global Pneumonia Testing Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 16 Global Pneumonia Testing Market Outlook, By Imaging Test (2021-2030) ($MN)
  • Table 17 Global Pneumonia Testing Market Outlook, By Sputum Test (2021-2030) ($MN)
  • Table 18 Global Pneumonia Testing Market Outlook, By Urine Test (2021-2030) ($MN)
  • Table 19 Global Pneumonia Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Pneumonia Testing Market Outlook, By Method (2021-2030) ($MN)
  • Table 21 Global Pneumonia Testing Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 22 Global Pneumonia Testing Market Outlook, By Point of Care Testing (2021-2030) ($MN)
  • Table 23 Global Pneumonia Testing Market Outlook, By Immunodiagnostics (2021-2030) ($MN)
  • Table 24 Global Pneumonia Testing Market Outlook, By Other Methods (2021-2030) ($MN)
  • Table 25 Global Pneumonia Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 26 Global Pneumonia Testing Market Outlook, By Enzyme Linked Immunosorbant Assay (2021-2030) ($MN)
  • Table 27 Global Pneumonia Testing Market Outlook, By Immunofluoroscence (2021-2030) ($MN)
  • Table 28 Global Pneumonia Testing Market Outlook, By Western Blot (2021-2030) ($MN)
  • Table 29 Global Pneumonia Testing Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 30 Global Pneumonia Testing Market Outlook, By Imunohistochemistry (2021-2030) ($MN)
  • Table 31 Global Pneumonia Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 32 Global Pneumonia Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Pneumonia Testing Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 34 Global Pneumonia Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 35 Global Pneumonia Testing Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 36 Global Pneumonia Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.